SEARCH:   Advanced

Blood, 1 June 2005, Vol. 105, No. 11, pp. 4170-4178. Prepublished online as a Blood First Edition Paper on February 8, 2005; DOI 10.1182/blood-2004-10-4077. This Article Full Text (PDF) All Versions of this Article: 2004-10-4077v1 105/11/4170    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Doyonnas, R. Articles by McNagny, K. M Search for Related Content PubMed PubMed Citation Articles by Doyonnas, R. Articles by McNagny, K. M Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 22, 2004 Accepted January 25, 2005 Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells Regis Doyonnas, Julie S Nielsen, Shierley Chelliah, Erin Drew, Takahiko Hara, Atsushi Miyajima, and Kelly M McNagny* The Biomedical Research Centre, The University of British Columbia, Vancouver, BC, Canada Tokyo Metropolitan Organization for Medical Research, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan Institute of Molecular and Cellular Biosciences, The University of Tokyo, Tokyo, Japan * Corresponding author; email: Kelly{at}brc.ubc.ca. Podocalyxin/PCLP1/Thrombomucin/MEP21 is a CD34-related sialomucin. We have performed a detailed analysis of its expression during murine development and assessed its utility as a marker of hematopoietic stem cells (HSC) and their more differentiated progeny. We find that Podocalyxin is highly expressed by the first primitive hematopoietic progenitors and nucleated red blood cells to form in the embryonic yolk sac. Likewise, Podocalyxin is expressed by definitive multilineage hematopoietic progenitors and erythroid precursors in fetal liver. The level of Podocalyxin expression gradually declines with further embryo maturation and reaches near-background levels at birth. This is followed by a postnatal burst of expression that correlates with the seeding of new hematopoietic progenitors to the spleen and bone marrow. Shortly thereafter, Podocalyxin expression gradually declines and by four weeks post-partum it is restricted to a rare population of Sca-1+, c-kit+, Lin- cells in the bone marrow. These rare Podocalyxin expressing cells are capable of serially reconstituting myeloid and lymphoid lineages in lethally irradiated recipients suggesting they have HSC activity. In summary, we find that Podocalyxin is a marker of embryonic HSC and erythroid cells and of adult HSC and that it may be a valuable marker for the purification of these cells for transplantation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. S. Nielsen and K. M. McNagny The Role of Podocalyxin in Health and Disease J. Am. Soc. Nephrol., August 1, 2009; 20(8): 1669 - 1676. [Abstract] [Full Text] [PDF] M. A. Schluter and B. Margolis Apical Lumen Formation in Renal Epithelia J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1444 - 1452. [Abstract] [Full Text] [PDF] P. Sathyanarayana, E. Houde, D. Marshall, A. Volk, D. Makropoulos, C. Emerson, A. Pradeep, P. J. Bugelski, and D. M. Wojchowski CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools Blood, May 14, 2009; 113(20): 4955 - 4962. [Abstract] [Full Text] [PDF] S. Kang, S. Elf, S. Dong, T. Hitosugi, K. Lythgoe, A. Guo, H. Ruan, S. Lonial, H. J. Khoury, I. R. Williams, et al. Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation Mol. Cell. Biol., April 15, 2009; 29(8): 2105 - 2117. [Abstract] [Full Text] [PDF] J. S. Nielsen and K. M. McNagny Novel functions of the CD34 family J. Cell Sci., November 15, 2008; 121(22): 3683 - 3692. [Abstract] [Full Text] [PDF] S. Sakao, L. Taraseviciene-Stewart, C. D. Cool, Y. Tada, Y. Kasahara, K. Kurosu, N. Tanabe, Y. Takiguchi, K. Tatsumi, T. Kuriyama, et al. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells FASEB J, November 1, 2007; 21(13): 3640 - 3652. [Abstract] [Full Text] [PDF] P. Sathyanarayana, M. P. Menon, O. Bogacheva, O. Bogachev, K. Niss, W. S. Kapelle, E. Houde, J. Fang, and D. M. Wojchowski Erythropoietin modulation of podocalyxin and a proposed erythroblast niche Blood, July 15, 2007; 110(2): 509 - 518. [Abstract] [Full Text] [PDF] C. Desponts, A. L. Hazen, K. H. T. Paraiso, and W. G. Kerr SHIP deficiency enhances HSC proliferation and survival but compromises homing and repopulation Blood, June 1, 2006; 107(11): 4338 - 4345. [Abstract] [Full Text] [PDF] A. Matsubara, A. Iwama, S. Yamazaki, C. Furuta, R. Hirasawa, Y. Morita, M. Osawa, T. Motohashi, K. Eto, H. Ema, et al. Endomucin, a CD34-like sialomucin, marks hematopoietic stem cells throughout development J. Exp. Med., December 5, 2005; 202(11): 1483 - 1492. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020